Regeneron Pharmaceuticals, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
Regeneron Pharmaceuticals reports increased net income and diluted EPS in 2025, driven by strong Dupixent sales, despite a significant decline in U.S. EYLEA revenue and ongoing regulatory and legal challenges.
NASDAQ
Regeneron's 2024 10-K filing reveals a year of revenue growth, pipeline progress, and strategic collaborations, alongside ongoing legal and regulatory challenges.
NASDAQ
Regeneron Pharmaceuticals' CEO and CFO have certified the accuracy and completeness of the company's 2023 annual report on Form 10-K, ensuring compliance with SEC regulations.